Noble Financial Sees Multiple Readouts for Heat Biologics (HTBX) by YE16; Maintains 'Buy' Rating

August 17, 2016 11:25 AM EDT
Get Alerts HTBX Hot Sheet
Price: $1.23 +1.65%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade HTBX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Noble Financial affirms Heat Biologics, Inc. (HTBX) with a Buy rating and $8 price target following recent Q2 results.

Analyst Kumaraguru Raja sees multiple readouts for Heat Bio by the end of the year. Key points include:

  • Potential candidate for acquisition or collaboration. ImPACT based clinical programs, HS-410 in non-muscle invasive bladder cancer (NMIBC), and HS-110 in combination with Opdivo in NSCLC are making progress. We believe that the company is undervalued and is potentially a candidate for acquisition or collaboration following data readouts in 4Q16
  • HS-110 preliminary data promising. HS-110 is currently in Phase 1b in combination with a PD-1 inhibitor (Opdivo) for advanced NSCLC, preliminary data showed that the combination did not lead to increased toxicity, responding patients had antigen-specific immune response to antigens in the vaccine and shared tumor antigens. HS-110 has potential to convert tumors in non-responders with low tumor infiltrating lymphocytes (TILs) to high TILs leading to response
  • ComPACT pre-clinical data promising. The ComPACT platform is a vaccine and a T cell co-stimulator in a single construct transfected in an allogeneic tumor cell line. Therefore, the ComPACT platform includes HSP gp96-Ig and a T cell co-stimulator such as OX40 ligand in a single construct/plasmid, preliminary pre-clinical data has been promising and has showed enhanced tumor rejection

For an analyst ratings summary and ratings history on Heat Biologics click here. For more ratings news on Heat Biologics click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Noble Financial, S1, Definitive Agreement

Add Your Comment